Effect of Human immune response on repeat courses of 131I-Chimeric B72.3 antibody therapy

Academic Article


  • As part of a phase I trial of 131I-chimeric B72.3 in patients with metastatic colorectal cancer, 9 patients received a second course of therapy 6-8 weeks following initial therapy. There was an excellent inverse correlation between their human anti-chimeric antibody (HACA) at time of second therapy and in vivo behavior of 131I-ch B72.3 including mean residence time in plasma, whole body half-life and marrow suppression. Three of 5 patients with normal or low levels of HACA at time of second therapy had improved radiolocalization of tumor sites while 3 of 4 patients with high HACA levels had negative scans at previously positive sites. These studies suggest that the levels of HACA can predict important in vivo parameters and no patients had any serious adverse effects of repeat therapy.
  • Authors

    Author List

  • Meredith RF; Khazaeli MB; Plott WE; Liu T; Russell CD; Wheeler RH; LoBuglio AF
  • Start Page

  • 39
  • End Page

  • 46
  • Volume

  • 6
  • Issue

  • 1